Introduction
============

Venous thromboembolism (VTE) represents a common clinical condition that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), with an overall annual incidence of 108 per 100,000 inhabitants in the USA.[@b1-ppa-10-073] In fact, PE and DVT are considered a different expression of the same clinical condition, since \~70% of patients with PE had a DVT, and 30%--70% of patients with DVT had a clinical or subclinical PE.[@b2-ppa-10-073] Physicians should always consider PE which represents a life-threatening condition, ranking second among causes of out-of-hospital sudden death in the general population,[@b3-ppa-10-073] and also in hospitalized patients, mortality due to PE is high.[@b4-ppa-10-073] For these reasons, treatment of VTE should be familiar to any clinician. Therapy of PE and DVT was based on anticoagulant approach with parenteral or subcutaneous heparin or oral anticoagulants, represented by warfarin or new oral anticoagulants (NOAs), such as apixaban, rivaroxaban, dabigatran, or endoxaban.[@b5-ppa-10-073] The vitamin K antagonists (VKAs) warfarin and acenocoumarol represent the old standard treatment for VTE, and their efficacy in prevention of recurrent VTE could be quantified as decreasing recurrent risk of \~3%.[@b6-ppa-10-073] The main limitations of this therapy are the need of frequent control of coagulation pattern (international normalized ratio, INR) with some costs and logistic discomfort for patients, possible food and drug interactions leading to alterations of anticoagulant effect, and high incidence of bleeding complications. Thus, a low adherence to this therapy could be an expected consequence, and trials dealing with patients on VKAs for VTE showed that poor adherence could be detected by low percent of time in therapeutic range and with an increased risk of thromboembolic complications.[@b7-ppa-10-073] NOAs include factor Xa inhibitors (rivaroxaban, apixaban, and endoxaban) and factor IIa inhibitors (dabigatran). NOAs do not require routine laboratory monitoring and frequent changes in dosage, suggesting an improvement in pharmacological adherence. However, results from a meta-analysis study of 18 randomized trials including \>100,000 patients showed that total study discontinuation rates were not significantly different between NOAs and conventional therapy in VTE and prevention of stroke in atrial fibrillation (AF), whereas drug discontinuation with NOAs was significantly higher than with placebo in acute coronary syndromes.[@b8-ppa-10-073] NOAs could suffer main drug interaction, and clinical contraindications could limit their potential use; however, these drugs do not require frequent evaluations of coagulation parameters and do not show changes in their pharmacological effectiveness related to foods or body weight.[@b9-ppa-10-073],[@b10-ppa-10-073] Moreover, NOAs are considered to be a favorable alternative to heparin in long-term VTE treatment, but bleeding risk and the absence of reversal agent are their major limitations.[@b11-ppa-10-073] However, only a few data are available on possible differences by sex in the prescription of drugs, even if a little more is known on the use of antiplatelet agents (APAs). Results from a multicenter study in Italy, aiming to evaluate the existence of sex differences in treatment at hospital admission and prescription at discharge, showed the presence of statistical differences, among others, for APAs. At admission, men were more likely to be on APAs (41.7% vs 36.7%; *P*=0.0029), and at discharge, APAs (43.7% vs 37.3%; *P*=0.0003) continued to be prescribed more often in men.[@b12-ppa-10-073] A recent study carried out in the Netherlands compared adherence to NOAs with adherence to APAs. Mean adherence to NOAs was 84.2% compared with 87.3% to APAs. One in four NOAs users had a percentage of days covered by medication \<80% compared with one in five APA users. No data by sex subgroups were available.[@b13-ppa-10-073]

Thus, due to the paucity of available data, we decided to put ourselves in patients' shoes, and the aim of this review was to analyze all adverse events (AEs) of apixaban compared to conventional therapy (heparin or VKAs) in randomized controlled trials (RCTs) of VTE treatment, with a particular attention to possible differences by sex.

Methods
=======

We performed a literature search of electronic databases, MEDLINE and Embase, using the keywords "apixaban" and "venous thromboembolism". The aim of this search was to identify all RCTs that analyze dapixaban for treatment and prevention of VTE, and the main outcome was the collection of data about AEs. AEs were classified as serious, bleeding, and cause of discontinuation. For any study, we required a minimum set of data, including author, journal and year of publication, and total number of patients treated with apixaban and/or with conventional therapy. Moreover, we made a comprehensive search by using the keywords "gender" and "venous thromboembolism" and "anticoagulants".

Results
=======

As for the first objective, 13 RCTs were identified, but only eleven were included in the analysis. Two RCTs were excluded because authors did not classified AEs as serious, bleeding, and cause of discontinuation.

[Table 1](#t1-ppa-10-073){ref-type="table"} reports the type of AEs considered only in studies in which subjects were treated with apixaban.[@b14-ppa-10-073]--[@b24-ppa-10-073] Considering all subjects enrolled in the eleven RCTs as a whole to investigate the occurrence of AEs, we extrapolated an events/subjects rate of 57.8% for AEs (6,445/11,144), 7.7% for serious AEs (975/12,647), 9.1% for bleeding events (1,229/13,454), and 3.2% for discontinuation of apixaban (421/13,039). The overall percentages of AEs related to the number of patients treated with apixaban are reported in [Figure 1](#f1-ppa-10-073){ref-type="fig"}.

[Table 2](#t2-ppa-10-073){ref-type="table"} shows the AEs in different studies comparing apixaban and conventional therapy. The percentage of AEs was lower in subjects treated with apixaban than in those treated with conventional VTE therapy (53 vs 56.3%) ([Figure 2](#f2-ppa-10-073){ref-type="fig"}).

[Table 3](#t3-ppa-10-073){ref-type="table"} provides additional data on the existence or not of subanalysis by sex in the studies comparing apixaban and conventional therapy.

Discussion
==========

The first observation of the present study is a confirmation of a lower prevalence of AEs related to VTE prevention and treatment with apixaban compared with conventional therapy. Total AEs were reported in 57.8% of patients, 9.1% had bleeding events, 7.7% had serious AEs, and only 3.2% of patients discontinued apixaban due to AEs. Apixaban is a selective inhibitor of factor Xa with an effect on inhibition of the conversion of prothrombin to thrombin,[@b25-ppa-10-073] recently approved by health authorities in Italy for the treatment and prevention of VTE (May 23, 2015), and previously, for prevention of cerebrovascular events in patients with AF (December 2, 2013). Peak plasma concentration of apixaban is reached after 3 hours post-dose, half-life is \~12 hours, and anticoagulant effect expires after 24 hours post-dose.[@b26-ppa-10-073] Oral bioavailability is \~52%; fixed therapeutical dosage, low hepatic metabolism (only 15%), and nonrenal metabolism allow minimal drug interactions and formations of reactive metabolites.[@b26-ppa-10-073] A recent meta-analysis on risk of major bleeding related to NOAs showed a higher risk of hip surgery, acute coronary syndrome, and thromboprophylaxis in medically ill patients.[@b27-ppa-10-073] The higher rate of major bleeding in these patients was related to longer duration of NOAs therapy and probably to the higher comorbidity. After the publication of the main RCTs with NOAs, several reviews analyzed the therapeutic potential and safety of NOAs compared with VKAs.[@b28-ppa-10-073] The meta-analysis performed by van der Hulle et al showed that NOAs had lower relative risk (RR) than conventional therapy for major gastrointestinal bleeding (−0.16%), major bleeding (−0.67%), clinically relevant nonmajor bleeding (−1.77%), and fatal bleeding (−0.09%).[@b29-ppa-10-073] These data were associated with an important efficacy of NOAs in reduction of recurrent VTE (−0.24%) and overall mortality (−0.10%). Similar results were reported by Kakkos et al, with a high safety of NOAs regarding bleeding events but only a non-inferiority in preventing recurrent symptomatic VTE and reduction of DVT.[@b30-ppa-10-073] Compared to placebo, NOAs had higher efficacy on reduction of VTE recurrence (7.24% vs 1.32%) associated with higher incidence of nonmajor bleeding events and any bleeding. On the contrary, major bleeding events were not statistically different in patients treated with NOAs and placebo.[@b30-ppa-10-073] An analysis performed by Mantha and Ansell on comparative efficacy of NOAs for the treatment of VTE showed that apixaban could have more effect in VTE prevention compared with dabigatran, rivaroxaban, and endoxaban, even if no statistical difference was detected.[@b31-ppa-10-073] Similarly, Kang and Sobieraj reported a significantly lower incidence of major bleeding in patients treated with apixaban than in those treated with dabigatran and endoxaban, including lower risk of the composite end point (major and clinically relevant bleeding) compared to other NOAs.[@b32-ppa-10-073] A further meta-analysis comparing NOAs in VTE patients showed no significant differences in risk for recurrent VTE, major bleeding, or all-cause mortality between the different molecules but identified that low dose of apixaban (2.5 mg BID) was related to less clinically significant nonmajor bleeding than other NOAs.[@b33-ppa-10-073] Therefore, apixaban has been reported to be an effective and safe alternative to conventional therapy for acute or long-term treatment of VTE and to have a more favorable safety profile compared to other therapies.[@b34-ppa-10-073] Moreover, apixaban characteristics were confirmed in patients with mild and moderate renal insufficiency compared to VKAs.[@b35-ppa-10-073] NOAs, compared to conventional therapy, represent an economically acceptable strategy for VTE prophylaxis also in surgical patients.[@b36-ppa-10-073] To this extent, apixaban is associated with the greatest reduction in medical costs (−\$918) compared to VTE patients treated with standard therapy.[@b37-ppa-10-073]

The second main observation from this study is that the variable "sex" is not considered so much. For example, occurrence of VTE in patients with cancer is associated with unfavorable prognosis, and VTE treatment is less effective and more complicated in cancer patients. Comparison of efficacy and safety between NOAs and VKAs in cancer patients has been reported, but there are no guideline recommendations for women-specific cancer types or women-specific issues in the prevention and treatment of VTE.[@b38-ppa-10-073] Only a very minimal part of the studies comparing apixaban vs conventional therapy takes sex into consideration. In the ARISTOTLE study, 11,785 (64.7%) men and 6,416 (35.3%) women with AF or flutter were randomized to receive either warfarin or apixaban. Results showed that women had a similar rate of stroke or systemic embolism but a lower risk of mortality and less clinically relevant bleeding than men.[@b39-ppa-10-073] As for the previously cited RCTs on treatment of VTE, only one study provided data on separate analysis by sex of either efficacy or safety of apixaban.[@b14-ppa-10-073] Such a lack of data on sex subgroups is rather surprising. In fact, women are at higher risk of VTE, even though age plays crucial role. Results from an epidemiologic study on hospitalization for PE in a large population of Northwestern Italy (60,853 patients, 59.6% females, mean age 73±14 years) found an overall crude incidence rate significantly higher for women compared with men (55.4 and 40.6 events per year per 100,000 inhabitants, respectively; *P*\<0.001), but this difference completely disappeared after standardization for age.[@b40-ppa-10-073] Again, women are at risk of VTE after total hip arthroplasty or total knee arthroplasty. A study on 14 retrospective case--control or prospective cohort studies, including 18,075 patients who developed VTE after total hip arthroplasty or total knee arthroplasty out of a total of 1,723,350 cases, found that three main risk factors were significantly associated with VTE: history of VTE, varicose vein, and congestive cardiac failure. However, authors recognized other six significant factors increasing VTE risk, such as female sex, age ≥80 years, hypertension, active cancer, obesity (BMI ≥30), and black race.[@b41-ppa-10-073] The outcome during the course of anticoagulant therapy may differ according to the patient's sex, but available data are not always univocal. According to the Spanish data from the Registro Informatizado Enfermedad Trombo Embólica Registry on \>47,000 patients, women (51% of total sample) were older, more likely presented with PE, and were more likely to have recent immobilization but less likely to have cancer than men. Compared with men, women had a lower rate of DVT recurrences, a higher rate of major bleeding, and higher mortality due to PE, although rate of PE recurrences was similar. However, on multivariable analysis, any influence of sex on the risk for recurrent DVT, major bleeding, or fatal PE was no longer statistically significant.[@b42-ppa-10-073] A subanalysis of the same registry focused on the outcome of cancer patients with acute VTE showed that, compared with men, women had a significantly lower rate of fatal bleeding and death, and a nonsignificantly lower rate of PE recurrences and major bleeding.[@b43-ppa-10-073] Also, the meta-analysis studies, mostly addressed to both AF and VTE patients, are not conclusive. A systematic review and meta-analysis was performed to determine if the risk of major bleeding may differ between men and women receiving anticoagulation for AF or VTE. Forty-two studies including \>94,000 patients were analyzed: 83% had AF and 17% had VTE; 37,250 patients (40%) were women. The RR of major bleeding for men vs women was 1.02, in particular 1.02 in patients with AF and 0.80 in patients with VTE. Thus, the risk of major bleeding on anticoagulation seems to be the same in both sexes, especially in the case of AF, whereas in patients with VTE, the risk of bleeding may be marginally lower in men compared with women.[@b44-ppa-10-073] Again, another recent comprehensive systematic review and meta-analysis of 13 studies (\>100,000 patients) showed that NOAs had a similar efficacy and safety compared with VKAs in female and male patients treated for nonvalvular AF and acute VTE. However, in the extended treatment of VTE, a trend toward an increased risk of bleeding in male patients as compared with female patients was observed for NOAs compared with placebo.[@b45-ppa-10-073]

As for low adherence to anticoagulant therapy, there are no univocal data available. Previous findings reported that risk factors related to lower adherence of VKAs therapy included younger age, male sex, poor cognitive function, poverty, and higher educational attainment.[@b46-ppa-10-073] In a study on a total of 2,068 patients in Denmark, performing self-management of VKAs, males achieved a significantly better therapeutic INR control than females. In fact, females spent 71.1% of the time within therapeutic INR target range, whereas males spent 76.4% (*P*\<0.0001), but the incidence of major complications was low and similar in both sexes.[@b47-ppa-10-073] Again, a Swedish study evaluated the persistence with presently available antithrombotic treatments in AF patients. The overall persistence with any oral anticoagulant was 88.2% at 1 year and 82.9% at 2 years. After 1 year, the crude persistence was 85.0% with warfarin, 85.9% with apixaban, 74.4% with dabigatran, and 77.4% with rivaroxaban. Multivariate analysis confirmed significantly higher persistence with warfarin and apixaban than with dabigatran or rivaroxaban, persistence at 1 year after initiations on warfarin, and that apixaban had higher odds for persistence than initiation on dabigatran and rivaroxaban. However, female sex was one of the factors significantly associated with lower persistence.[@b48-ppa-10-073] On the contrary, different results were reported by a recent study aimed to assess self-reported anticoagulation adherence in a tertiary center anticoagulation clinic. Main indications for anticoagulation were VTE (72%) and AF (18%); 74% of patients were on VKAs, and 26% on NOAs (rivaroxaban 79%, dabigatran 19%, apixaban 2%). Predictors of anticoagulation adherence were, in decreasing order, use of additional oral medications (odds ratio \[OR\] =2.78), retired employment status (OR =2.31), female sex (OR =1.58), and age (OR =1.02). In multivariate analyses, age, female sex, and use of other oral medications remained significantly associated with anticoagulation adherence.[@b49-ppa-10-073]

In conclusion, in the patient's perspective, apixaban could represent a good choice in the treatment of VTE, due to its pharmacological, economical, and safety profile. These positive aspects are probably present in both sexes, since the available studies include a correct percentage of women. Future clinical trials should include in their results on clinical impact and outcomes a stratification by sex, and studies aimed to evaluate possible sex-related differences for these drugs should be strongly encouraged.
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###### 

Type of AEs in studies in which subjects were treated with apixaban

  Author                                            Journal, year              Selection criteria       Total patients   Total serious adverse events   n
  ------------------------------------------------- -------------------------- ------------------------ ---------------- ------------------------------ -------
  Agnelli et al[@b14-ppa-10-073]                    *N Engl J Med*, 2013       DVT or PE                2,676            All AEs                        1,795
                                                                                                                         Serious AEs                    417
                                                                                                                         Bleeding AEs                   415
                                                                                                                         Discontinuations due to AEs    162
  Agnelli et al[@b15-ppa-10-073]                    *N Engl J Med*, 2013       DVT                      1,651            All AEs                        1,138
                                                                                                                         Serious AEs                    219
                                                                                                                         Discontinuations due to AEs    128
  Goldhaber et al[@b16-ppa-10-073]                  *N Engl J Med*, 2011       DVT                      3,184            Bleeding AEs                   246
  Lassen et al[@b17-ppa-10-073]                     *N Engl J Med*, 2009       Postoperative DVT        1,596            All AEs                        135
                                                                                                                         Serious AEs                    --
                                                                                                                         Bleeding AEs                   85
  Lassen et al[@b18-ppa-10-073]                     *N Engl J Med*, 2010       Postoperative DVT        2,673            All AEs                        1,752
                                                                                                                         Serious AEs                    184
                                                                                                                         Bleeding AEs                   268
                                                                                                                         Discontinuations due to AEs    91
  Levine et al[@b19-ppa-10-073]                     *J Thromb Haemost*, 2012   VTE in cancer patients   93               All AEs                        8
                                                                                                                         Bleeding AEs                   6
  Lassen et al[@b20-ppa-10-073]                     *J Thromb Haemost*, 2007   Postoperative DVT        917              All AEs                        797
                                                                                                                         Serious AEs                    80
                                                                                                                         Bleeding AEs                   62
                                                                                                                         Discontinuations due to AEs    108
  Botticelli Investigators et al[@b21-ppa-10-073]   *J Thromb Haemost*, 2008   Symptomatic DVT          392              Bleeding AEs                   6
                                                                                                                         Discontinuations due to AEs    50
  Lassen et al[@b22-ppa-10-073]                     *Lancet*, 2010             Postoperative DVT        1,501            All AEs                        786
                                                                                                                         Serious AEs                    72
                                                                                                                         Bleeding AEs                   90
                                                                                                                         Discontinuations due to AEs    40
                                                                                                                         Drug-related AEs               207
                                                                                                                         Drug-related serious AEs       16
  Nakamura et al[@b23-ppa-10-073]                   *Circ J*, 2015             DVT                      37               All AEs                        34
                                                                                                                         Serious AEs                    3
                                                                                                                         Bleeding AEs                   7
                                                                                                                         Discontinuations due to AEs    0
  Barrett et al[@b24-ppa-10-073]                    *Thromb Haemost*, 2011     DVT                      385              Bleeding AEs                   44

**Abbreviations:** AEs, adverse events; DVT, deep vein thrombosis; PE, pulmonary embolism; --, data not given.

###### 

AEs in different studies comparing apixaban and conventional therapy

  Author                                            Journal, year              Selection criteria   Total apixaban patients, n   AEs in patients treated with apixaban, n   Total patients in conventional therapy, n   AEs in patients treated with conventional therapy, n
  ------------------------------------------------- -------------------------- -------------------- ---------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------------------
  Agnelli et al[@b14-ppa-10-073]                    *N Engl J Med*, 2013       DVT or PE            2,676                        1,795                                      2,689                                       1,923
  Lassen et al[@b17-ppa-10-073]                     *N Engl J Med*, 2009       Postoperative DVT    1,596                        135                                        1,588                                       136
  Lassen et al[@b18-ppa-10-073]                     *N Engl J Med*, 2010       Postoperative DVT    2,673                        1,752                                      2,659                                       1,811
  Lassen et al[@b20-ppa-10-073]                     *J Thromb Haemost*, 2007   Postoperative DVT    917                          797                                        300                                         263
  Botticelli Investigators et al[@b21-ppa-10-073]   *J Thromb Haemost*, 2008   Symptomatic DVT      392                          50                                         128                                         10
  Lassen et al[@b22-ppa-10-073]                     *Lancet*, 2010             Postoperative DVT    1,501                        786                                        1,508                                       836
  Nakamura et al[@b23-ppa-10-073]                   *Circ J*, 2015             DVT                  40                           34                                         39                                          37
  Barrett et al[@b24-ppa-10-073]                    *Thromb Haemost*, 2011     DVT                  385                          44                                         126                                         20

**Abbreviations:** AEs, adverse events; DVT, deep vein thrombosis; PE, pulmonary embolism.

###### 

Evaluation by sex in the studies comparing apixaban and conventional therapy

  Author (journal, year)                                                       Distribution by sex   Apixaban                  Anticoagulant               Efficacy by sex     Safety by sex
  ---------------------------------------------------------------------------- --------------------- ------------------------- --------------------------- ------------------- -------------------
  Agnelli et al[@b14-ppa-10-073] (*N Engl J Med*, 2013)                        Apixaban: M 58.3%     M 9/1,561                 M 24/1,591                  Apixaban better     Apixaban better
                                                                               Eno/War: M 59.1%      F 6/1,115                 F 25/1,098                  No sex difference   No sex difference
  Lassen et al[@b17-ppa-10-073] (*N Engl J Med*, 2009)                         Apixaban: F 62.4%     Major 11/1,596            Major 22/1,588              Not given           Not given
                                                                               Eno: F 61.8%          Nonmajor 35/1,596         Nonmajor 47/1,588                               
  Lassen et al[@b18-ppa-10-073] (*N Engl J Med*, 2010)                         Apixaban: F 52.8%     Major 22/2,673            Major 18/2,659              Not given           Not given
                                                                               Eno: F 53.8%          Nonmajor 109/2,673        Nonmajor 120/2,659                              
  Lassen et al[@b20-ppa-10-073] (*J Thromb Haemost*, 2007)                     Total: F 63.3%        Major 0%--3.2%            Major: Eno 0%, War 0%       Not given           Not given
                                                                               Apixaban              Minor 7.2%                Minor: Eno 4.0%, War 5.3%                       
                                                                               Eno                                                                                             
                                                                               Warfarin                                                                                        
  Botticelli Investigators et al[@b21-ppa-10-073] (*J Thromb Haemost*, 2008)   Total: M 62%          Major and CRNM 28/392     Major and CRNM 10/128       Not given           Not given
                                                                               Apixaban              Minor 19/382              Minor 10/128                                    
                                                                               LMWH/VKAs                                                                                       
  Lassen et al[@b22-ppa-10-073] (*Lancet*, 2010)                               Apixaban: F 71%       Major and CRNM 53/1,501   Major and CRNM 72/1,508     Not given           Not given
                                                                               Eno: F 74%            Minor 51/1,501            Minor 54/1,508                                  
  Nakamura et al[@b23-ppa-10-073] (*Circ J*, 2015)                             Apixaban: F 45%       All bleeds 7/40           All bleeds 17/39            Not given           Not given
                                                                               UFH/War: F 57.5%                                                                                

**Abbreviations:** M, male; Eno, enoxaparin; War, warfarin; F, female; LMWH, low-molecular weight heparin; VKAs, vitamin K antagonists; CRNM, clinically relevant nonmajor; UFH, unfractionated heparin.
